- The key vendors in the global hemophilia-A market 2015-2019 are Baxter International, Novo Nordisk, Bayer, Pfizer and CSL Behring
London, 29 September 2015: Technavio, an independent tech-focused global research firm, has announced the publication of its market research report on the global hemophilia-A market 2015-2019. There are new technological advancements in terms of drug manufacturing, development, and delivery. These advances has led to the development of recombinant products. The increased use of technology may result in therapies with greater safety and acceptance. The global hemophilia A drugs market is expected to grow at a CAGR of 6.25% during the forecast period of 2014-2019.
“The prophylactic treatment approach increases the quality of life in terms of physical activities, retains the level of clotting factors above a baseline, and prevents spontaneous bleeding episodes,” says Faisal Ghaus, Vice President of Technavio Research.
“Drugs with favorable pharmacokinetic profiles are fast gaining traction to avoid inconvenience to people, including pain at the injection site. Long-acting formulations reduce repeated dosing.”
To define the market conditions in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
